GlassScriptPhysician profile
Carl L Murray
NPI 1447241906
$1,620.43
in general payments reported to CMS, 2019-2025
19 companies · $29.18 in 2025
The $29.18 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $386 · 2021: $444 · 2022: $85.92 · 2023: $191 · 2024: $198 · 2025: $29.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.72 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $237.07 | 2019-2024 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $197.78 | 2021-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.39 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $104.79 | 2019-2021 | |
| Exact Sciences Corporation | $65.74 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $65.00 | 2019-2021 | |
| Pfizer INC. | $53.39 | 2020 | |
| Abbott Laboratories | $49.32 | 2023 | Cardiomems |
| Teva Pharmaceuticals USA, INC. | $40.52 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $33.25 | 2023-2024 | Ingrezza |
| Allergan, INC. | $32.56 | 2019-2020 | |
| Atricure, INC. | $29.18 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Arbor Pharmaceuticals, INC. | $22.63 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.80 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.94 | 2023 | Watchman |
| Lilly USA, LLC | $15.70 | 2024 | Mounjaro |
| Abbvie INC. | $14.18 | 2022 | |
| Amarin Pharma, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.